ZA201309161B - Peptide compositions and methods for treating lung injury, asthma, anaphylaxis, angioedema, systemic vascular permeability syndromes, and nasal congestion - Google Patents

Peptide compositions and methods for treating lung injury, asthma, anaphylaxis, angioedema, systemic vascular permeability syndromes, and nasal congestion

Info

Publication number
ZA201309161B
ZA201309161B ZA2013/09161A ZA201309161A ZA201309161B ZA 201309161 B ZA201309161 B ZA 201309161B ZA 2013/09161 A ZA2013/09161 A ZA 2013/09161A ZA 201309161 A ZA201309161 A ZA 201309161A ZA 201309161 B ZA201309161 B ZA 201309161B
Authority
ZA
South Africa
Prior art keywords
angioedema
anaphylaxis
asthma
methods
lung injury
Prior art date
Application number
ZA2013/09161A
Other languages
English (en)
Inventor
Yulia A Komarova
Uzma Saqib
Stephen M Vogel
Asrar B Malik
Original Assignee
Univ Illinois
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Illinois filed Critical Univ Illinois
Publication of ZA201309161B publication Critical patent/ZA201309161B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/033—Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the internal surface of the plasma membrane, e.g. containing a myristoylation motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
ZA2013/09161A 2011-06-13 2013-12-05 Peptide compositions and methods for treating lung injury, asthma, anaphylaxis, angioedema, systemic vascular permeability syndromes, and nasal congestion ZA201309161B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161496409P 2011-06-13 2011-06-13
PCT/US2012/042118 WO2012174028A2 (en) 2011-06-13 2012-06-13 Peptide compositions and methods for treating lung injury, asthma, anaphylaxis, angioedema, systemic vascular permeability syndromes, and nasal congestion

Publications (1)

Publication Number Publication Date
ZA201309161B true ZA201309161B (en) 2015-03-25

Family

ID=47357694

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2013/09161A ZA201309161B (en) 2011-06-13 2013-12-05 Peptide compositions and methods for treating lung injury, asthma, anaphylaxis, angioedema, systemic vascular permeability syndromes, and nasal congestion

Country Status (15)

Country Link
US (2) US9248198B2 (enExample)
EP (1) EP2717897B1 (enExample)
JP (1) JP6042425B2 (enExample)
KR (1) KR102042015B1 (enExample)
CN (2) CN106188232B (enExample)
AU (1) AU2012271781C1 (enExample)
BR (1) BR112013032108B1 (enExample)
CA (1) CA2838662C (enExample)
DK (1) DK2717897T3 (enExample)
ES (1) ES2633343T3 (enExample)
IL (1) IL229771B (enExample)
MX (1) MX349146B (enExample)
PL (1) PL2717897T3 (enExample)
WO (1) WO2012174028A2 (enExample)
ZA (1) ZA201309161B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102042015B1 (ko) * 2011-06-13 2019-11-07 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 폐 손상, 천식, 과민증, 혈관 부종, 전신 혈관 투과성 증후군 및 비충혈을 치료하는 펩티드 조성물과 이들로 이러한 질환을 치료하는 방법
DK3265110T3 (da) * 2015-03-02 2020-10-19 The Board Of Trustees Of The Univ Of Illionis Peptider til inhibering af angiogenese
CN110128506B (zh) * 2019-05-22 2021-03-30 中国药科大学 一种寡肽及其应用
CN110664990B (zh) * 2019-11-07 2021-03-16 江南大学 一种trpc1肽类分子在制备治疗病毒感染引起的炎症的药物中的应用
US20230218710A1 (en) * 2020-04-15 2023-07-13 Cohbar, Inc. Method of treating coronavirus infections

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US6093740A (en) * 1997-04-30 2000-07-25 Eli Lilly And Company Therapeutic treatment for skin disorders
GB9718609D0 (en) * 1997-09-02 1997-11-05 Imp College Innovations Ltd Fusion protein
CA2545062A1 (en) * 2003-11-06 2005-05-26 Research Development Foundation Selective inhibitors of nuclear factor-kb activation and uses thereof
KR101260717B1 (ko) * 2003-12-03 2013-05-09 와이엠 바이오사이언시즈 오스트레일리아 피티와이 엘티디 튜불린 저해제
KR20080075494A (ko) * 2005-09-21 2008-08-18 다스크 테크날러지, 엘엘씨 장기 및 조직 기능성을 위한 방법 및 조성물
US7585865B2 (en) * 2006-07-21 2009-09-08 The Penn State Research Foundation Protein kinase C zeta inhibition to treat vascular permeability
CA2657338C (en) * 2006-07-21 2013-10-22 Cristalia Produtos Quimicos Farmaceuticos Ltda. Anti-inflammatory and antiallergic cyclic peptides
WO2009094172A2 (en) * 2008-01-22 2009-07-30 Araim Pharmaceuticals, Inc. Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
FR2940032B1 (fr) 2008-12-23 2013-08-09 Seb Sa Panier de cuisson d'aliments et systeme de cuisson correspondant
IT1392567B1 (it) * 2008-12-24 2012-03-09 Bioindustry Park Del Canavese S P A Uso di un peptide derivato da er-alfa per il ripristino della sensibilita' a composti antiestrogenici in cellule di tumore mammario
US20100190691A1 (en) 2009-01-27 2010-07-29 Trojan Technologies, Ltd Delivery of nucleic acids using cell-penetrating peptides
KR102042015B1 (ko) * 2011-06-13 2019-11-07 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 폐 손상, 천식, 과민증, 혈관 부종, 전신 혈관 투과성 증후군 및 비충혈을 치료하는 펩티드 조성물과 이들로 이러한 질환을 치료하는 방법

Also Published As

Publication number Publication date
EP2717897A2 (en) 2014-04-16
AU2012271781C1 (en) 2017-09-21
EP2717897B1 (en) 2017-04-19
WO2012174028A3 (en) 2013-02-21
CA2838662A1 (en) 2012-12-20
DK2717897T3 (en) 2017-07-17
MX349146B (es) 2017-07-14
CN103608026A (zh) 2014-02-26
KR102042015B1 (ko) 2019-11-07
CA2838662C (en) 2018-07-24
MX2013014650A (es) 2014-01-24
CN103608026B (zh) 2016-08-24
PL2717897T3 (pl) 2017-09-29
US9248198B2 (en) 2016-02-02
AU2012271781A1 (en) 2014-01-09
US20140155314A1 (en) 2014-06-05
AU2012271781B2 (en) 2017-02-16
US20140213505A1 (en) 2014-07-31
IL229771B (en) 2019-07-31
US8912139B2 (en) 2014-12-16
ES2633343T3 (es) 2017-09-20
EP2717897A4 (en) 2015-01-07
BR112013032108B1 (pt) 2021-10-26
JP2014518211A (ja) 2014-07-28
BR112013032108A2 (pt) 2016-11-22
WO2012174028A2 (en) 2012-12-20
JP6042425B2 (ja) 2016-12-14
CN106188232A (zh) 2016-12-07
KR20140056185A (ko) 2014-05-09
CN106188232B (zh) 2020-01-07

Similar Documents

Publication Publication Date Title
ZA201400792B (en) Novel piperidono-dihydrothienopyrimidine sulfoxides and their use for treating copd and asthma
PL3272234T3 (pl) Artykuły do palenia i inne artykuły dostarczające przepływ
KR102169542B9 (ko) 흡연 물품 및 흡입 재료를 산출하기 위한 그 사용
IL232226A0 (en) Albumin-binding antibodies and their binding fragments
PL2657008T3 (pl) Zespół sprężarki powietrza do montażu na pojeździe
SG11201501110XA (en) Inhalation systems, breathing apparatuses, and methods
SG11201408767UA (en) Rare-earth contained y type molecular sieve and preparation method thereof
EP2214712A4 (en) COMPOSITIONS AND METHODS FOR TREATING ASTHMA AND PULMONARY DISORDERS
EP2736197A4 (en) METHOD, DEVICE AND SYSTEM FOR PACKET COMPOSITION AND RESEQUENCING
LT2729151T (lt) Farmacinė kompozicija, gydymo būdai ir jų panaudojimas
EP2655309A4 (en) METHODS AND COMPOSITIONS FOR TREATING LUNG CANCER
ZA201109492B (en) Compositions comprising finafloxacin and methods for treating ophthalmic,otic,or nasal infections
EP2500054A4 (en) GAS FOG INHALER
AU339359S (en) Respiratory mask and/or components thereof
EP2679264A4 (en) INHALER OF GASEOUS MIST
ZA201309161B (en) Peptide compositions and methods for treating lung injury, asthma, anaphylaxis, angioedema, systemic vascular permeability syndromes, and nasal congestion
PL2484916T3 (pl) Sprężarka odśrodkowa mająca dyfuzor o zmiennej geometrii oraz sposób
GB2505810B (en) Nasal aroma breathing pipe
EP2734149A4 (en) DEVICES AND METHODS FOR BREATHING TREATMENT AFFECTED BY SLEEP DISORDERS
ZA201308248B (en) Pack for cigarettes as well as precut part, material web, and method for the manufacture thereof
EP2626065A4 (en) INHIBITABLE COMPOSITION COMPOSITION FOR THE TREATMENT OF ASTHMA
WO2012048115A3 (en) Polypeptides and their use in treating and limiting respiratory syncytial virus infection
PL2935044T3 (pl) Opakowanie na artykuły do palenia i sposób wytwarzania opakowania
HUE042102T2 (hu) Acilezetlen grelin fragmensek Prader-Willi szindróma kezelésében történõ alkalmazásra
EP2925436A4 (en) METAL PHOSPHATE MOLECULAR SIEBE, METHOD FOR THE PREPARATION AND USE